|6th January 2021||Jerome B Zeldis||1,650||Grant/award etc.||$0.00|
|28th May 2020||Jerome B Zeldis||1,000||Open or private purchase||$10.49||$10,488.90|
|29th January 2020||Jerome B Zeldis||1,650||Grant/award etc.||$0.00|
|19th November 2019||Christopher J Schaber||10,770||Open or private purchase||$0.93||$10,016.10|
|19th November 2019||Jerome B Zeldis||2,000||Open or private purchase||$0.93||$1,850.00|
|23rd September 2019||Diane L. Parks||14,940||Open or private purchase||$0.93||$13,870.30|
|19th September 2019||Jerome B Zeldis||4,000||Open or private purchase||$0.94||$3,740.00|
|28th June 2019||Mark E. Pearson||78,338||Grant/award etc.||$0.71||$55,619.98|
|22nd May 2019||Jerome B Zeldis||1,097||Exercise of derivative||$6.85||$7,514.45|
|22nd May 2019||Jerome B Zeldis||20,000||Exercise of derivative||$3.40||$68,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. The company operates through the following segments: BioTherapeutics and Vaccines/BioDefense. It offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of T-cell lymphoma.